Brokerages Set Haemonetics Corp. (HAE) Price Target at $34.57
Shares of Haemonetics Corp. (NYSE:HAE) have received a consensus rating of “Hold” from the eleven brokerages that are covering the company. Two analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $34.57.
Several brokerages have weighed in on HAE. Barrington Research upgraded Haemonetics Corp. from a “market perform” rating to an “outperform” rating and set a $41.00 target price for the company in a report on Tuesday, November 8th. BTIG Research restated a “neutral” rating on shares of Haemonetics Corp. in a research note on Monday, November 7th. Benchmark Co. upped their price objective on Haemonetics Corp. from $32.00 to $34.00 and gave the stock a “hold” rating in a research note on Monday, November 7th. Off Wall Street started coverage on Haemonetics Corp. in a research note on Friday, October 14th. They set a “sell” rating and a $24.00 price objective for the company. Finally, CJS Securities cut Haemonetics Corp. from a “market outperform” rating to a “market perform” rating and set a $35.00 price objective for the company. in a research note on Tuesday, September 20th.
Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Haemonetics Corp. by 125.7% in the first quarter. BlackRock Inc. now owns 3,501 shares of the company’s stock worth $122,000 after buying an additional 1,950 shares during the period. Acrospire Investment Management LLC acquired a new stake in Haemonetics Corp. during the third quarter worth approximately $123,000. Tower Research Capital LLC TRC acquired a new stake in Haemonetics Corp. during the second quarter worth approximately $133,000. D.A. Davidson & CO. boosted its stake in Haemonetics Corp. by 0.6% in the third quarter. D.A. Davidson & CO. now owns 4,079 shares of the company’s stock worth $147,000 after buying an additional 25 shares during the period. Finally, PineBridge Investments L.P. raised its position in shares of Haemonetics Corp. by 4.2% in the second quarter. PineBridge Investments L.P. now owns 6,473 shares of the company’s stock worth $187,000 after buying an additional 261 shares in the last quarter. Institutional investors own 98.96% of the company’s stock.
WARNING: This story was originally posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The correct version of this story can be read at https://www.thecerbatgem.com/2016/11/27/brokerages-set-haemonetics-corp-hae-price-target-at-34-57.html.
Haemonetics Corp. (NYSE:HAE) opened at 39.89 on Tuesday. The stock has a 50 day moving average price of $36.16 and a 200-day moving average price of $33.30. The firm’s market capitalization is $2.06 billion. Haemonetics Corp. has a one year low of $25.98 and a one year high of $39.94.
Haemonetics Corp. (NYSE:HAE) last issued its earnings results on Monday, November 7th. The company reported $0.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.35 by $0.11. Haemonetics Corp. had a positive return on equity of 10.99% and a negative net margin of 6.48%. The business earned $220.30 million during the quarter, compared to analysts’ expectations of $210.72 million. During the same period in the prior year, the business earned $0.44 EPS. The business’s revenue for the quarter was up .3% compared to the same quarter last year. On average, analysts predict that Haemonetics Corp. will post $1.50 earnings per share for the current fiscal year.
Haemonetics Corp. Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Stock Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related stocks with our FREE daily email newsletter.